Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco- and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a variety of in vitro tests under various conditions, which makes a quantitative comparison questionable. METHOD: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRalpha expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). RESULTS AND CONCLUSIONS: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the Delta1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16alpha-methyl or 16beta-methyl group). Almost ideal GCs in terms of missing MC effects, as defined by our in vitro assay, are therefore prednylidene, budesonide, beclomethasone and betamethasone.The MC potency of a steroid is increased by a 9alpha- or a 6alpha-fluoro substituent. A hydrophilic substituent in position 16 (like 16-hydroxylation in triamcinolone) decreases both MC and GC properties. As no substituent that leads to an isolated reduction of GC activity could be characterized in our experiments, 9alpha-fluorocortisol, the most frequently used steroid for MC substitution, seems to be the best choice of available steroids for this purpose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“For example, regarding triamcinolone, its relatively low receptor affinity, both for MRs and GRs, contrasts with its high in vivo potency [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Furthermore, the presence of the 6α-methyl group diminishes the MC activity in vivo, as shown for 6α-methylprednisolone, which presents lower MC activity, but higher GC activity compared with prednisolone [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Functional domains of the human glucocorticoid receptor
Giguère, V., Hollenberg, S. M., Rosenfeld, M. G., & Evans, R. M. (1986) · Cell · doi:10.1016/0092-8674(86)90339-9 · Cited by 918
Differential Recognition of Target Genes by Nuclear Receptor Monomers, Dimers, and Heterodimers*
GLASS, C. K. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-391 · Cited by 829
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818 · cited 1×
“Comparing the influence of further functional groups on transactivation via the hGR and the hMR will help to understand the structure ( 52 , 53) and functionality of the substrate binding sites in these receptors.”
BackgroundChandler, V. L., Maler, B. A., & Yamamoto, K. R. (1983) · Cell · doi:10.1016/0092-8674(83)90430-0 · Cited by 667
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110033251406 · Cited by 541
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor
Reichardt, H. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7168 · Cited by 429
Transcriptional cross-talk, the second mode of steroid hormone receptor action
Göttlicher, M., Heck, S., & Herrlich, P. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050242 · Cited by 388
Cited by
Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.120 · Cited by 922
“Furthermore, PMD patients demonstrate a blunted response to fludrocortisone, a mixed mineralocorticoid/ glucocorticoid agonist (12, 14), high rates of non-suppression on challenge with dexamethasone, with particularly high post-dexamethasone cortisol levels (13).”
BackgroundSchiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
“active glucocorticoid [74,75], while the 11-keto androgens are more potent than their 11β-hydroxy counterparts [76].”
A users guide to HPA axis research
Spencer, R. L., & Deak, T. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.014 · Cited by 405
“1 nM), cortisol and corticosterone with a lower affinity (Kd ~3-5 nM), and aldosterone with a much lower affinity (151,152).”
Early-life stress and HPA axis trigger recurrent adulthood depression
Juruena, M. F. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.10.020 · Cited by 253
“[87] contrasted the MR and GR properties of different steroids that are regularly used in clinical practice in the equal in vitro test system complemented by a system to test the steroid binding affinities (see Fig.”
BackgroundMethodInfluentialTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“In contrast, a hydrophilic substituent at position 16 decreases both MC and GC properties (20).”
BackgroundFrom Receptor Balance to Rational Glucocorticoid Therapy
de Kloet, E. R. (2014) · Endocrinology · doi:10.1210/en.2014-1048 · Cited by 208
“Although this compound is clinically mostly used in low doses as MR agonist during adrenal deficiency or postural hypotension, it is actually a potent mixed agonist of both MR and GR (165).”
BackgroundThe brain mineralocorticoid receptor and stress resilience
ter Heegde, F., De Rijk, R. H., & Vinkers, C. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.022 · Cited by 187
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
“Furthermore, it has been confirmed that aldosterone (which is often described as possessing no GC activity) shows GR-mediated transactivation at concentrations relative to cortisol that are not even reached neither in primary hyperaldosteronism nor in replacement therapy with fludrocortisone [65].”
BackgroundMethodInfluentialStress and Depression: a Crucial Role of the Mineralocorticoid Receptor
de Kloet, E. R., Otte, C., Kumsta, R., Kok, L., Hillegers, M. H. J., Hasselmann, H., Kliegel, D., & Joëls, M. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12379 · Cited by 178
“The use of fludrocortisone may have another benefit as well since the compound is about six fold more potent than cortisol in GR-mediated effects (122).”
Salt, A. N., & Plontke, S. K. (2018) · Hearing Research · doi:10.1016/j.heares.2018.03.002 · Cited by 176
“Potency is influenced by the affinity of the cytosolic glucocorticoid and/or mineralocorticoid receptors to the drug and on the ability of the drug to penetrate the cell membrane to reach the cytosolic receptors (Grossmann et al., 2004).”
Redefining the perioperative stress response: a narrative review
Manou-Stathopoulou, V., Korbonits, M., & Ackland, G. L. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.08.011 · Cited by 148
Salter, M., Biggadike, K., Matthews, J. L., West, M. R., Haase, M. V., Farrow, S. N., Uings, I., & Gray, D. W. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00108.2007 · Cited by 158
“However, some GR ligands have been shown to have affinity for other steroid hormone receptors (8, 11).”
BackgroundDevelopment of a Concise Synthesis of Ouabagenin and Hydroxylated Corticosteroid Analogues
Renata, H., Zhou, Q., Dünstl, G., Felding, J., Merchant, R. R., Yeh, C., & Baran, P. S. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512022r · Cited by 143
Tegethoff, M., Pryce, C., & Meinlschmidt, G. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0014 · Cited by 140
“Due to these structural alterations, synthetic analogs of endogenous glucocorticoids exhibit comparatively intensified potency at the GR and reduced activity at the mineralocorticoid receptor [MR (the symbol approved by the HUGO Nomenclature Committee is NR3C2)] (10).”
BackgroundEpigenetic programming of the neuroendocrine stress response by adult life stress
Dirven, B. C. J., Homberg, J. R., Kozicz, T., & Henckens, M. J. A. G. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0019 · Cited by 138
Otte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K., & Kellner, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.10.006 · Cited by 129
“Fludrocortisone has some affinity for GR although much lower compared to its affinity to MR (Grossmann et al., 2004).”
BackgroundNewton, R., Leigh, R., & Giembycz, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.003 · Cited by 132
Russell, G. M., Henley, D. E., Leendertz, J., Douthwaite, J. A., Wood, S. A., Stevens, A., Woltersdorf, W. W., Peeters, B. W. M. M., Ruigt, G. S. F., White, A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5332-09.2010 · Cited by 111
“…have predominately used the potent glucocorticoid agonist dexamethasone to inhibit HPA activity over long time domains and have been used in the investigation of affective disorders or Cushing’s disease (Schmider et al., 1995; Deuschle et al., 1998; Castro et al., 2003; Grossmann et al., 2004).”
BackgroundMethodInfluentialUse of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0167 · Cited by 120
Nehmé, A., Lobenhofer, E. K., Stamer, W. D., & Edelman, J. L. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-58 · Cited by 104
“Moreover, a wide range of GR binding affinities have been reported in the literature for each of these three GCs [35].”
Intratympanic corticosteroids for sudden sensorineural hearing loss
Plontke, S. K., Meisner, C., Agrawal, S. K., Cayé‐Thomasen, P., Galbraith, K., Mikulec, A. A., Parnes, L. S., Premakumar, Y., Reiber, J., Schilder, A. G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008080.pub2 · Cited by 160
Prete, A., Taylor, A. E., Bancos, I., Smith, D. J., Foster, M. A., Kohler, S., Fazal-Sanderson, V., Komninos, J., O’Neil, D. M., Vassiliadi, D. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa133 · Cited by 96
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
Heier, C. R., Yu, Q., Fiorillo, A. A., Tully, C., Tucker, A., Mázala, D. A. G., Uaesoontrachoon, K., Srinivassane, S., Damsker, J. M., Hoffman, E. P., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800186 · Cited by 99
“We and others fi nd that de fl azacort shows increased speci fi city for the GR, with reduced or absent effects on the MR (Grossmann et al, 2004).”
BackgroundOtte, C., Wingenfeld, K., Kuehl, L. K., Kaczmarczyk, M., Richter, S., Quante, A., Regen, F., Bajbouj, M., Zimmermann-Viehoff, F., Wiedemann, K., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.181 · Cited by 91
Glucocorticoid Signaling and Epigenetic Alterations in Stress-Related Disorders
Mourtzi, N., Sertedaki, A., & Charmandari, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115964 · Cited by 86
“On the other hand, MRs are predominantly expressed in limbic areas (hippocampus, amygdala and prefrontal cortex) together with GRs [17], and are characterized by a 10-fold higher binding affinity for glucocorticoids than GRs [18].”
BackgroundMechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy
Quattrocelli, M., Zelikovich, A. S., Salamone, I. M., Fischer, J. A., & McNally, E. M. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200556 · Cited by 96
“Synthetic glucocorticoids such as deflazacort [24], prednisone [25], and dexamethasone [26] have less affinity for MR [27].”
Backgroundvan Leeuwen, N., Kumsta, R., Entringer, S., de Kloet, E. R., Zitman, F. G., DeRijk, R. H., & Wüst, S. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.07.006 · Cited by 102
Von Werne Baes, C., de Carvalho Tofoli, S. M., Martins, C. M. S., & Juruena, M. F. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00610.x · Cited by 80
“Thus, these studies preferentially investigate the functioning of GR receptors in depression (10,17,18,20,24).”
BackgroundZhao, M., Bousquet, E., Valamanesh, F., Farman, N., Jeanny, J., Jaisser, F., & Béhar‐Cohen, F. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7675 · Cited by 82
“05 nM).(29,31,32) We have previously shown that in the normal rat retina, Kir4.”
BackgroundInfluentialGarbrecht, M. R., Klein, J. M., Schmidt, T. J., & Snyder, J. M. (2006) · Neonatology · doi:10.1159/000088653 · Cited by 72
“Additionally, two recent studies have demonstrated that the 11-keto metabolite of Dex (11-dehydro Dex) can compete for GC binding to the GR and act as a potent GR agonist [ , , ,”
BackgroundMyers, B., & Greenwood-Van Meerveld, B. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00298.2009 · Cited by 70
“In a luciferase transactivation assay, Aldo showed a MR potency that was over 100 times higher than Dex whereas the reported GR potency of Dex was 300 times that of Aldo (17).”
Glucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Juruena, M. F., Baes, C. V. W., Menezes, I. C., & Graeff, F. G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150105125500 · Cited by 75
“However, the most important of these similarities is that prednisolone and cortisol are similar in their abilities to bind and activate MR as much as GR, especially when compared to dexamethasone [86, 93].”
BackgroundAtkinson, H. C., Wood, S. A., Castrique, E. S., Kershaw, Y. M., Wiles, C. C. R., & Lightman, S. L. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00721.2007 · Cited by 68
“This was achieved by rapid administration via an intravenous bolus of methylprednisolone, a corticosteroid with both MR and GR activity and of ALDO, a predominantly MR agonist (20).”
BackgroundMethodInfluentialQuantitation of Glucocorticoid Receptor DNA-Binding Dynamics by Single-Molecule Microscopy and FRAP
Groeneweg, F. L., van Royen, M. E., Fenz, S. F., Keizer, V. I. P., Geverts, B., Prins, J., de Kloet, E. R., Houtsmuller, A. B., Schmidt, T. S., & Schaaf, M. J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090532 · Cited by 71
“Importantly, all hormones were administered at a saturating concentration (1 mM), thus the fraction of bound receptor should be similar for all ligands [4,40,42,43].”
BackgroundBanciu, M., Metselaar, J. M., Schiffelers, R. M., & Storm, G. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.05.004 · Cited by 63
Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
Biggar, W. D., Skalsky, A. J., & McDonald, C. M. (2022) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210776 · Cited by 77
“Deflazacort has little to no affinity for the human mineralocorticoid receptor, and the active metabolite, deflazacort-21-hydroxide, shows low transactivation [22].”
BackgroundHirsch, G., Lavoie‐Lamoureux, A., Beauchamp, G., & Lavoie, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044606 · Cited by 73
“These conclusions are based on in vivo human and animal studies and in vitro experiments using a transactivation assay of cells transfected with human GR [32].”
BackgroundMethodInfluentialRole of mineralocorticoid receptors on the hypothalamus–pituitary–adrenal axis in humans
Berardelli, R., Karamouzis, I., D’Angelo, V., Zichi, C., Fussotto, B., Giordano, R., Ghigo, E., & Arvat, E. (2012) · Endocrine · doi:10.1007/s12020-012-9750-8 · Cited by 74
Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis
Koning, A.-S. C. A. M., van der Meulen, M., Schaap, D., Satoer, D., Vinkers, C. H., van Rossum, E. F. C., van Furth, W. R., Pereira, A. M., Meijer, O. C., & Dekkers, O. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad701 · Cited by 73
Early Life Stress in Depressive Patients: HPA Axis Response to GR and MR Agonist
Baes, C. V. W., Martins, C. M. S., Tofoli, S. M. D. C., & Juruena, M. F. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00002 · Cited by 60
“It might also be useful to allow comparison of male and female subjects to ascertain, whether sex steroids and menopausal status can influence HPA axis dysfunction and other hormones like ACTH and aldosterone, the most selective hormone to bind to MR, which could be measured concomitantly to improve the overall assess…”
BackgroundPrimary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy
Esposito, D., Pasquali, D., & Johannsson, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01928 · Cited by 59
“In vitro studies reported that FC exhibited a 10-fold higher GC potency than that of cortisol (26).”
BackgroundQuinkler, M., Ekman, B., Marelli, C., Uddin, S., Zelissen, P., Murray, R. D., & _, _. (2017) · Endocrine Connections · doi:10.1530/ec-16-0081 · Cited by 59
Hemmerling, M., Nilsson, S., Edman, K., Eirefelt, S., Russell, W., Hendrickx, R., Johnsson, E., Mårdh, C. K., Berger, M., Rehwinkel, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01215 · Cited by 59
Differential glucocorticoid effects on proliferation and invasion of human trophoblast cell lines
Mandl, M., Ghaffari-Tabrizi, N., Haas, J., Nöhammer, G., & Desoye, G. (2006) · Reproduction · doi:10.1530/rep.1.00976 · Cited by 57
“JAR cells were used as negative control in this study to identify a potential involvement of the mineralocorticoid receptor in GC effects, because GCs can also transactivate this receptor (Grossmann et al. 2004).”
MethodBrey, D. M., Motlekar, N. A., Diamond, S. L., Mauck, R. L., Garino, J. P., & Burdick, J. A. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22925 · Cited by 56
Buckley, T. M., Mullen, B. C., & Schatzberg, A. F. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.05.016 · Cited by 53
“Compared to fludrocortisone, the potency of these agents is much lower at MR (Grossmann et al., 2004).”
BackgroundPrednisolone exerts exquisite inhibitory properties on platelet functions
Liverani, E., Banerjee, S., Roberts, W., Naseem, K. M., & Perretti, M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.006 · Cited by 52
“Pred and fludrocortisone have shown an higher affinity for GR, but can also bind the mineralocorticoid receptor (MR) [20,21], Dex binds strictly bind GR [20], while”
BackgroundLiebau, A., Pogorzelski, O., Salt, A. N., & Plontke, S. K. (2017) · Otology & Neurotology · doi:10.1097/mao.0000000000001254 · Cited by 54
“One study based on the activation kinetics of the signal cascades in the glucocorticoid receptor and mineralocorticoid receptor (Table 3) suggests that the calculated intracochlear drug concentrations achieved by the evaluated treatment protocols could induce drug-mediated changes in inner ear tissue (42).”
BackgroundMineralocorticoid receptor function and cognition in health and disease
Wingenfeld, K., & Otte, C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.09.010 · Cited by 53
Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling
Sedlak, D., Paguio, A., & Bartunek, P. (2011) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620711795222446 · Cited by 52
“3a and Table 1c) was expected and is consistent with data in the literature [19].”
ResultMineralocorticoid substitution and monitoring in primary adrenal insufficiency
Quinkler, M. O., Oelkers, W., Remde, H., & Allolio, B. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.008 · Cited by 64
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Macrophages and liposomes in inflammatory disease: Friends or foes?
Crielaard, B. J., Lammers, T., Morgan, M. E., Chaabane, L., Carboni, S., Greco, B. M., Zaratin, P., Kraneveld, A. D., & Storm, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.045 · Cited by 53
“Dexamthasone is found to be 6–10 times more potent than prednisolone nd 5 times more potent than 6 -methylprednisolone with respect o their glucocorticoid activities (Gilman and Goodman, 2006; rossmann et al., 2004).”
BackgroundAndrews, M. H., Wood, S. A., Windle, R. J., Lightman, S. L., & Ingram, C. D. (2011) · Endocrinology · doi:10.1210/en.2011-1434 · Cited by 50
“We have shown (9) that although the mineralocorticoid receptor (MR)-selective agonist aldosterone (250 g) has a transient suppressive effect on corticosterone levels, injection of methylprednisolone (which has one tenth of the MR activity of aldosterone but 20-fold greater GR activity) (47) had a much greater and long…”
BackgroundEngels, M., Pijnenburg-Kleizen, K. J., Utari, A., Faradz, S. M. H., Oude-Alink, S., van Herwaarden, A. E., Span, P. N., Sweep, F. C., & Claahsen-van der Grinten, H. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00547 · Cited by 43
“Several studies have been performed evaluating the binding of steroids to the GR and mineralocorticoid receptor and/or the nuclear translocation of the receptor complex, but only a few studies report on GR transactivation (9–14), mainly focusing on aldosterone and cortisol, showing that cortisol has higher potency for…”
BackgroundPaul, S. N., Wingenfeld, K., Otte, C., & Meijer, O. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15835 · Cited by 49
“Aldosterone dissociates from MR more slowly, and the receptor undergoes several ligandreceptor conformational changes (Grossmann et al., 2004).”
BackgroundLeclère, M., Lefebvre-Lavoie, J., Beauchamp, G., & Lavoie, J. (2010) · Equine Veterinary Journal · doi:10.1111/j.2042-3306.2009.00022.x · Cited by 47
“…be approximately 6–12 times more potent than prednisolone based on human and animal studies (approximately 25 and 4 times cortisol potency, respectively) and in vitro experiments using cells transfected with human glucocorticoid receptor (21 and 1.7 times cortisol potency) (Grossmann et al. 2004).”
BackgroundInfluentialOwen, D., & Matthews, S. G. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01517.x · Cited by 44
Stewart, P. M., & Krone, N. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00015-8 · Cited by 61
Adrenal cortex and its disorders
Miller, W. L., & Flück, C. E. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00022-6 · Cited by 60
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study
Bretagne, M., Lebrun‐Vignes, B., Pariente, A., Shaffer, C. M., Malouf, G. G., Dureau, P., Potey, C., Funck‐Brentano, C., Roden, D. M., Moslehi, J. J., et al. (2019) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.09.006 · Cited by 49
Hodgkinson, T., Tsimbouri, P. M., Llopis-Hernández, V., Campsie, P., Scurr, D. J., Childs, P. G., Phillips, D. J., Donnelly, S., Wells, J. A., O’Brien, F. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb7921 · Cited by 46
A Glucocorticoid Sensitive Biphasic Rhythm of Testosterone Secretion
Waite, E., Kershaw, Y., Spiga, F., & Lightman, S. (2009) · Journal of neuroendocrinology · doi:10.1111/j.1365-2826.2009.01900.x · Cited by 45
Corticosteroids and Immune Suppressive Therapies in Horses
Leclère, M. (2017) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2016.11.008 · Cited by 46
Preclinical Studies of Low Back Pain
Strong, J. A., Xie, W., Bataille, F. J., & Zhang, J. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-17 · Cited by 37
“Interpretation of this experiment is confounded by the fact that prednisolone can activate both MR and GR in vitro [51].”
Meijer, O. C., & de Kloet, E. R. (2016) · Endocrinology · doi:10.1210/en.2016-1495 · Cited by 41
Drug-induced endocrine blood pressure elevation
Beck, K. R., Thompson, G. R., & Odermatt, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104311 · Cited by 42
Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice
Banciu, M., Fens, M. H. A. M., Storm, G., & Schiffelers, R. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.008 · Cited by 37
“Indeed, the data show that the antitumor potency of the LCL-GC formulation can strongly depend on the potency of the type of GC encapsulated, as the antitumor activity induced by LCL-BUP is much higher when compared to that of the other LCL-GC formulations (budesonide has 250-fold higher potency compared to cortisol w…”
ResultSalt, A. N., Hartsock, J. J., Hou, J., & Piu, F. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00347 · Cited by 40
Context Modulates Outcome of Perinatal Glucocorticoid Action in the Brain
de Kloet, E. R., Claessens, S. E. F., & Kentrop, J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00100 · Cited by 39
“Second, the synthetic glucocorticoids bind the GR with higher affinity than endogenous glucocorticoids (9).”
BackgroundInfluentialPijnenburg-Kleizen, K. J., Engels, M., Mooij, C. F., Griffin, A., Krone, N., Span, P. N., van Herwaarden, A. E., Sweep, F. C. G. J., & Claahsen-van der Grinten, H. L. (2015) · Endocrinology · doi:10.1210/en.2015-1087 · Cited by 35
“The EC50 of cortisol in our model is comparable to the EC50 previously described (16), demonstrating the reliability of our in vitro model.”
ResultFrindt, G., Yang, L., Bamberg, K., & Palmer, L. G. (2018) · The Journal of Physiology · doi:10.1113/jp275988 · Cited by 35
“Assuming a Kd of the GR for aldosterone of 160 nM (Grossmann et al. 2004) and negligible competition from corticosterone as a result of 11β-HSD activity, the GR could be as much as 20%”
BackgroundMa, K., Hu, M., Qi, Y., Qiu, L., Jin, Y., Yu, J., & Li, B. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.042 · Cited by 34
“However, opposite to the effect observed with the GR, the D1-dehydro-configuration and the 16a-methyl and 16b-methyl groups attenuate MC potency [27].”
BackgroundMikami, K., Kiyokawa, Y., Ishii, A., & Takeuchi, Y. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104654 · Cited by 34
Nguyen Dinh Cat, A., Ouvrard-Pascaud, A., Tronche, F., Clemessy, M., Gonzalez-Nunez, D., Farman, N., & Jaisser, F. (2009) · Endocrinology · doi:10.1210/en.2008-1531 · Cited by 34
Wu, A., Wolley, M. J., & Stowasser, M. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0170-6 · Cited by 36
Transcriptional glucocorticoid effects in the brain: Finding the relevant target genes
Meijer, O. C., Buurstede, J. C., Viho, E. M. G., Amaya, J. M., Koning, A.-S. C. A. M., van der Meulen, M., van Weert, L. T. C. M., Paul, S. N., Kroon, J., & Koorneef, L. L. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13213 · Cited by 40
“The ligand binding of MR and GR differs also for mineralocorticoids (aldosterone binds MR in cell types where cortisol is enzymatically degraded) and binding of synthetic glucocorticoids, in varying degrees.(30) For synthetic glucocorticoids with a very low MR affinity, this may have consequences for the neuropsychiat…”
Backgroundde Souza, R. R., Bó, S. D., de Kloet, E. R., Oitzl, M. S., & Carobrez, A. P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.017 · Cited by 32
Rapid signaling of steroid hormones in the vertebrate nervous system
Sakamoto, H., Takahashi, H., Matsuda, K.-I., Nishi, M., Takanami, K., Ogoshi, M., Sakamoto, T., & Kawata, M. (2011) · Frontiers in bioscience · doi:10.2741/3970 · Cited by 32
“These effects differ from those in mammals in which MR and GR can both be activated by aldosterone and glucocorticoids (189, 193).”
BackgroundGarbrecht, M. R., Krozowski, Z. S., Snyder, J. M., & Schmidt, T. J. (2006) · Steroids · doi:10.1016/j.steroids.2006.06.001 · Cited by 30
Koorneef, L. L., van der Meulen, M., Kooijman, S., Sánchez-López, E., Scheerstra, J. F., Voorhoeve, M. C., Ramesh, A. N. N., Rensen, P. C. N., Giera, M. A., Kroon, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.960279 · Cited by 33
“Dexamethasone has a higher affinity for GR than for the MR (14), which leads to a much higher stimulation of GR in vivo (15).”
BackgroundFernandes, E. C. A., Bovee, T. F. H., Daamen, F. E. J., Helsdingen, R. J. R., van den Berg, M., & van Duursen, M. B. M. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.07.008 · Cited by 35
Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., Chae, W. R., Salchow, P., Abu-Tir, I., Piber, D., Hellmann‐Regen, J., & Otte, C. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0789-7 · Cited by 35
Berardelli, R., Karamouzis, I., Marinazzo, E., Prats, E., Picu, A., Giordano, R., Ghigo, E., & Arvat, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1076 · Cited by 31
The Adrenal Cortex and Its Disorders
Miller, W. L., Achermann, J. C., & Flück, C. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50017-x · Cited by 33
Mooij, C. F., Parajes, S., Pijnenburg-Kleizen, K. J., Arlt, W., Krone, N., & Claahsen-van der Grinten, H. L. (2015) · Hormone Research in Paediatrics · doi:10.1159/000374112 · Cited by 27
Pharmacokinetics of Dexamethasone Solution following Intratympanic Injection in Guinea Pig and Sheep
Wang, X., Fernandez, R., Dellamary, L. A., Harrop, A., Ye, Q., Lichter, J., Lau, D., LeBel, C. P., & Piu, F. (2010) · Audiology and Neurotology · doi:10.1159/000320611 · Cited by 27
“In addition, the high affinity of dexamethasone for its targets (glucocorticoid and mineralocorticoid receptors) [Grossmann et al., 2004] constitutes another attractive property that led to the selection of dexamethasone in this study, as opposed to other steroids.”
ResultQi, Y., Klyubin, I. V., Ondrejčák, T., Hu, N., & Rowan, M. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01056-9 · Cited by 29
Ye, L., Xie, W., Strong, J. A., & Zhang, J. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000277 · Cited by 30
Preterm lung and brain responses to mechanical ventilation and corticosteroids
Hillman, N. H., & Jobe, A. H. (2023) · Journal of Perinatology · doi:10.1038/s41372-023-01692-7 · Cited by 27
“In contrast, hydrocortisone weakly activates both the glucocorticoid (1/25th the af fi nity of dexamethasone) and the mineralocorticoid receptors [67, 71].”
BackgroundWeikum, E. R., Okafor, C. D., D’Agostino, E. H., Colucci, J. K., & Ortlund, E. A. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108506 · Cited by 26
“3B) (Yoneda et al., 1995; Bledsoe et al., 2002; Grossmann et al., 2004; Nehmé et al., 2009).”
BackgroundGlucocorticoid therapy regulates podocyte motility by inhibition of Rac1
McCaffrey, J., Webb, N. J. A., Poolman, T. M., Fresquet, M., Moxey, C., Zeef, L. A. H., Donaldson, I. J., Ray, D. W., & Lennon, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-06810-y · Cited by 24
The Genetic Basis of Primary Aldosteronism
Funder, J. W. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0255-x · Cited by 28
Pfau, A. C., Großmann, C., Freudinger, R., Mildenberger, S., Benesic, A., & Gekle, M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.10.002 · Cited by 24
Claessens, S. E. F., Belanoff, J. K., Kanatsou, S., Lucassen, P. J., Champagne, D. L., & de Kloet, E. R. (2012) · Brain Research · doi:10.1016/j.brainres.2012.08.017 · Cited by 29
“For example, it has been suggested that DEX, although it has a substantially higher affinity for GR, binds to MR as well (Grossmann et al., 2004; Rupprecht et al., 1993; van Leeuwen et al., 2009).”
BackgroundSchultebraucks, K., Wingenfeld, K., Otte, C., & Quinkler, M. O. (2015) · Neuroendocrinology · doi:10.1159/000438791 · Cited by 26
Lauridsen, T. G., Vase, H. Ø., Bech, J. N., Nielsen, S., & Pedersen, E. B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0030 · Cited by 23
Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease
Srinivasan, M., & Lahiri, D. K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0277-5 · Cited by 26
“Glucocorticoids exhibit tenfold higher affinity for MR than GR [5, 6].”
Nachawi, N., Li, D., & Lansang, M. C. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23039 · Cited by 34
“23,24 Frequency and timing of administration.”
Metadata
- Authors
- Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Institute of Human Nutrition (DE)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 151
- Issue
- 3
- Pages
- 397-406
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2102136926
- Cited by
- 212
- References
- 51
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 15 · 2022: 12 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 10 · 2016: 13 · 2015: 10 · 2014: 18 · 2013: 5 · 2012: 11
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- glucocorticoid receptor, mineralocorticoid receptor, synthetic glucocorticoids, mineralocorticoid activity, structure-activity relationship, prednisolone, budesonide, beclomethasone, betamethasone, triamcinolone, steroid binding affinity
- MeSH terms
- Animals, Anti-Inflammatory Agents, Cells, Cultured, Chlorocebus aethiops, Dexamethasone, Glucocorticoids, Humans, Hydrocortisone, Kidney, Prednisolone, Pregnadienes, Receptors, Glucocorticoid, Transfection, Receptors, Mineralocorticoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.